Non-pharmacological control of atherosclerosis

动脉粥样硬化的非药物控制

基本信息

  • 批准号:
    7986579
  • 负责人:
  • 金额:
    $ 38.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Inflammatory nature of atherosclerosis and the vulnerability of the plaque have suggested the need to identify agents that would inhibit these processes in the treatment of the disease. We recently observed that the administration of sesame oil to atherosclerotic mice not only reduced the blood lipids by 50% but also prevented atherosclerosis by over 85%. Preliminary results indicated that sesame oil inhibited the expression of pro-inflammatory genes and genes related to plaque vulnerability while it enhanced the expression of genes involved in reverse cholesterol transport. There are two potential possibilities-.-these effects are due hitherto unknown effects of the fatty acid constituents of sesame oil (It contains almost equal amounts of mono and polyunsaturated fatty acids), or due to its unusual non-saponifiable components. The results also posed an important question, whether lowering of plasma lipids themselves resulted in the decrease of inflammation and promoted plaque stability and increased reverse cholesterol transport or the gene effects of sesame oil or its constituents were responsible for the observed decrease in lipids and atherosclerosis. Sesame oil contains equal amounts of mono- and poly unsaturated fatty acids and contains bio-active non-saponifiable components that are potent antioxidants and PPAR1 agonists. The overall goal of the study is to determine the mechanisms by which fatty acid components and non- saponifiable components of sesame oil could exert beneficial in atherosclerosis. In lieu of vitamin E's failure in protecting human atherosclerosis, identification of the mechanisms by which the non-saponifiable components of sesame oil might complement the anti-atherosclerotic effects of dietary unsaturated fat could lead to major new pharmacological alternatives and directions. The Goals of the proposed studies are: 1. To compare the efficacy of sesame oil with sunflower oil in its anti-atherosclerotic effects with using LDL receptor knockout animals and to delineate and identify the anti-atherosclerotic effects of its non- saponifiable components. 2. Identify the anti-atherosclerotic genes that are regulated by sesame oil and its saponifiable and non- saponifiable components and to define potential molecular mechanisms that may be involved in their action. 3. To determine whether sesame oil supplementation decrease markers of cardiovascular risk in normal and high risk human subjects. Implications: Dietary prevention of atherosclerosis has major advantages to pharmacological control, being inexpensive, sensible, and healthy. The proposed study could lead to the identification of components that could be "cheap" alternatives to expensive medication offering valuable "adjunct therapy" to existing medications, It would also lead to new class of drug development. PUBLIC HEALTH RELEVANCE: We recently identified that feeding sesame oil inhibited atherosclerosis. Analysis of genes affected by feeding sesame oil indicated that components of sesame oil inhibited several facets of atherosclerosis, including blood lipids, genes involved in cholesterol transport, inflammation, and the stability of the plaque. In the proposed study we plan to determine whether sesame oil possesses additional components with anti-atherosclerotic properties distinct from what could be ascribed to its fatty acid constituents. Dietary prevention of atherosclerosis has major advantages to pharmacological control, being inexpensive, sensible, and healthy. The proposed study could lead to the identification of components that could be "cheap" alternatives to expensive medication and also by offering valuable "adjunct therapy" to existing medications,
描述(由申请人提供):动脉粥样硬化的炎性性质和斑块的脆弱性表明有必要确定在疾病治疗中抑制这些过程的药物。我们最近观察到,给动脉粥样硬化小鼠服用芝麻油不仅可以降低50%的血脂,而且可以预防85%以上的动脉粥样硬化。初步结果表明,芝麻油抑制了促炎基因和斑块易损性相关基因的表达,而促进了胆固醇反向转运相关基因的表达。有两种潜在的可能性-这些影响是由于芝麻油的脂肪酸成分(它含有几乎等量的单不饱和脂肪酸和多不饱和脂肪酸)的迄今未知的影响,或者是由于其不寻常的非皂化成分。这一结果也提出了一个重要的问题,降低血脂本身是否导致炎症减轻、促进斑块稳定性和增加胆固醇反向转运,或者芝麻油或其成分的基因效应是导致观察到的血脂下降和动脉粥样硬化的原因。芝麻油含有等量的单不饱和脂肪酸和多不饱和脂肪酸,并含有生物活性的非皂化成分,这些成分是有效的抗氧化剂和PPAR1激动剂。这项研究的总体目标是确定芝麻油的脂肪酸成分和非皂化成分在动脉粥样硬化中发挥有益作用的机制。不同于维生素E在预防人类动脉粥样硬化方面的失败,识别芝麻油的非皂化成分可能补充饮食不饱和脂肪的抗动脉粥样硬化作用的机制可能会导致重大的新的药理替代和方向。本研究的目的是:1.利用低密度脂蛋白受体基因敲除动物模型,比较芝麻油和葵花籽油的抗动脉粥样硬化作用,并描述和鉴定其非皂化成分的抗动脉粥样硬化作用。2.鉴定受芝麻油及其皂化和非皂化成分调控的抗动脉粥样硬化基因,并确定可能参与其作用的潜在分子机制。3.确定补充芝麻油是否会降低正常人和高危人群的心血管危险标志物。饮食预防动脉粥样硬化与药物控制相比有很大的优势,廉价、敏感和健康。这项拟议的研究可能导致确定可能是昂贵药物的“廉价”替代品的成分,为现有药物提供有价值的“辅助治疗”,它还将导致新的药物开发类别。 公共卫生相关性:我们最近发现,食用芝麻油可以抑制动脉粥样硬化。对喂食芝麻油影响的基因的分析表明,芝麻油的成分可以抑制动脉粥样硬化的几个方面,包括血脂、参与胆固醇运输的基因、炎症和斑块的稳定性。在这项拟议的研究中,我们计划确定芝麻油是否具有与其脂肪酸成分不同的抗动脉粥样硬化特性的额外成分。饮食预防动脉粥样硬化与药物控制相比具有成本低、敏感和健康的主要优点。这项拟议的研究可能导致确定可能是昂贵药物的“廉价”替代品的成分,并通过为现有药物提供有价值的“辅助疗法”,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sampath Parthasarathy其他文献

Sampath Parthasarathy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sampath Parthasarathy', 18)}}的其他基金

Role of aldehyde oxidation in atherosclerosis
醛氧化在动脉粥样硬化中的作用
  • 批准号:
    8824965
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Role of aldehyde oxidation in atherosclerosis
醛氧化在动脉粥样硬化中的作用
  • 批准号:
    8721678
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
BMP-7 induced Macrophage Polarization in Atherosclerosis
BMP-7 诱导动脉粥样硬化中的巨噬细胞极化
  • 批准号:
    8896859
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
BMP-7 induced Macrophage Polarization in Atherosclerosis
BMP-7 诱导动脉粥样硬化中的巨噬细胞极化
  • 批准号:
    8723277
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
BMP-7 induced Macrophage Polarization in Atherosclerosis
BMP-7 诱导动脉粥样硬化中的巨噬细胞极化
  • 批准号:
    8599047
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
Non-pharmacological control of atherosclerosis
动脉粥样硬化的非药物控制
  • 批准号:
    8400472
  • 财政年份:
    2010
  • 资助金额:
    $ 38.13万
  • 项目类别:
Non-pharmacological control of atherosclerosis
动脉粥样硬化的非药物控制
  • 批准号:
    8665394
  • 财政年份:
    2010
  • 资助金额:
    $ 38.13万
  • 项目类别:
Non-pharmacological control of atherosclerosis
动脉粥样硬化的非药物控制
  • 批准号:
    8286089
  • 财政年份:
    2010
  • 资助金额:
    $ 38.13万
  • 项目类别:
Non-pharmacological control of atherosclerosis
动脉粥样硬化的非药物控制
  • 批准号:
    8530158
  • 财政年份:
    2010
  • 资助金额:
    $ 38.13万
  • 项目类别:
Non-pharmacological control of atherosclerosis
动脉粥样硬化的非药物控制
  • 批准号:
    8090508
  • 财政年份:
    2010
  • 资助金额:
    $ 38.13万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了